Newsbenzinga
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain
· Published
Article summary
Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.
An excerpt from the original article.
Comments —
Loading comments…